Targeting angiogenesis for mammary cancer prevention: Factors to consider in experimental design and analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 7, 2004, Pages 1173-1184

  Thompson, Henry J ^a   McGinley, John N ^a   Wolfe, Pamela ^a   Spoelstra, Nicole S ^a   Knott, Katrina K ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CANCER PREVENTION; CARCINOMA IN SITU; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRECANCER; PREVALENCE; PRIORITY JOURNAL; RAT; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CARCINOGENS; CARCINOMA IN SITU; FEMALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; RESEARCH DESIGN;

EID: 3142727946     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Vainio H. Targeting angiogenesis - a novel mode in cancer chemoprevention. Asian Pac J Cancer Prev 2003;4:83-6.
2. Bisacchi D, Benelli R, Vanzetto C, Ferrari N, Tosetti F, Albini A. Antiangiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 2003;27:229-38.
3. Pfeffer U, Ferrari N, Morini M, Benelli R, Noonan DM, Albini A. Antiangiogenic activity of chemopreventive drugs. Int J Biol Markers 2003;18:70-4.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
5. Brem SS, Jensen HM, Gullino, PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978;41:239-44.
6. Ottinetti A, Sapino A. Morphometric evaluation of microvessels surrounding hyperplastic and neoplastic mammary lesions. Breast Cancer Res Treat 1988;11:241-8.
7. Fregene TA, Kellogg CM, Pienta KJ. Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: A marker for precancerous disease. Int J Oncol 1994;4:1199-202.
8. Guinebretiere JM, Le Monique G, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease [letter; comment]. J Natl Cancer Inst 1994;86:635-6.
9. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994;86:614-9.
10. Heffelfinger SC, Yassin R, Miller MA, Lower E. Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. Clin Cancer Res 1996;2:1873-8.
11. Heffelfinger SC, Miller MA, Yassin R, Gear R. Angiogenic growth factors in preinvasive breast disease. Clin Cancer Res 1999;2867-76.
12. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78.
13. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst 1973;50:1111-8.
14. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
15. Wellings SR. A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract 1980;166:515-35.
16. Singh M, McGinley JN, Thompson HJ. A comparison of the histopathology of premalignant and malignant mammary gland lesions induced in sexually immature rats with those occurring in the human. Lab Invest 2000;80:221-31.
17. Maiorana A, Gullino PM. Acquisition of angiogenic capacity and neoplastic transformation in the rat mammary gland. Cancer Res 1978;38:4409-14.
18. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977;195:880-2.
19. Heffelfinger SC, Gear RB, Taylor K, et al. DMBA-induced mammary pathologies are angiogenic in vivo and in vitro. Lab Invest 2000; 80:485-92.
20. Gimbrone MA Jr, Gullino PM. Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. J Natl Cancer Inst 1976;56:305-18.
21. Gimbrone MA Jr, Gullino PM. Angiogenic capacity of preneoplastic lesions of the murine mammary gland as a marker of neoplastic transformation. Cancer Res 1976;36:2611-20.
22. Gullino PM. Natural history of breast cancer. Progression from hyperplasia to neoplasia as predicted by angiogenesis. Cancer 1977; 39:2697-703.
23. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst 1978; 61:639-43.
24. Jensen HM, Chen I, DeVault MR, Lewis AE. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982;218:293-5.
25. Gullino PM, Pettigrew HM, Grantham FH. N-nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst 1975;54: 401-14.
26. Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 1995;16: 2407-11.
27. McGinley JN, Knott KK, Thompson HJ. Semi-automated method of quantifying vasculature of 1-methyl-1-nitrosourea-induced rat mammary carcinomas using immunohistochemical detection. J Histochem Cytochem 2002;50:213-22.
28. Thompson HJ, Singh M, McGinley J. Classification of premalignant and malignant lesions developing in the rat mammary gland after injection of sexually immature rats with 1-methyl-1-nitrosourea. J Mammary Gland Biol Neoplasia 2000;5:201-10.
29. Weidner N, Folkman J. Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol 1996;167-90.
30. Thompson HJ, McGinley JN, Knott KK, Spoelstra NS, Wolfe P. Vascular density profile of rat mammary carcinomas induced by 1-methyl-1-nitrosourea: implications for the investigation of angiogenesis. Carcinogenesis 2002;23:847-54.
31. Long JS, Freese J. Redicted probabilities for count models. STATA J 2001;1:51-7.
32. Tobin J. Estimation of relationships for limited dependent variables. Econometrica 1958;26:24-36.
33. Westfall PH, Young SS. Resampling-based multiple testing. New York: John Wiley & Sons; 1993.
34. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley & Sons; 1999.
35. Thompson HJ, McGinley JN, Wolfe P, Singh M, Steele VE, Kelloff GJ. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis 1998;19:2181-5.
36. Heffelfinger SC, Gear RB, Schneider J, et al. TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen. Lab Invest 2003;83: 1001-11.
37. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers & Prev 2003;12:933-9.
38. Masso-Welch PA, Zangani D, Ip C, et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res 2002;62:4383-9.
39. Jiang C, Jiang W, Ip C, Ganther H, Lu J. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999;26:213-25.
40. Russo J, Russo IH. Boundaries in mammary carcinogenesis. Basic Life Sci 1991;57:43-57.